At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
sodium nitroprusside +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double-Blind, Placebo-Controlled, Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia
In Brief
A Phase 2 clinical trial evaluating sodium nitroprusside and Placebo for Schizophrenia. Completed, enrolled 60 participants across 4 sites.
Detailed Summary
The primary objective of this study is to investigate whether a single infusion of intravenous sodium nitroprusside (0.5 μg/kg/min for 4 hours) is superior to placebo (5% dextrose solution) at in treating positive and negative symptoms of schizophrenia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
CollaboratorsStanley Medical Research Institute
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartMay 2015
Primary CompletionMar 2017
Study CompletionApr 2017
TodayJul 2026
First PostedJun 17, 2014
Enrollment StartMay 1, 2015
Primary CompletionMar 31, 2017
Study CompletionApr 5, 2017
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 12.0 years ago
Interventions
sodium nitroprussidedrug
intravenous
Placeboother
Placebo